Expertise in
1
conditions

Dr. Kevin D. Cannon

Hospital Medicine
Wilmington Health PLLC
1202 Medical Ctr Dr, 
Wilmington, NC 
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
Wilmington Health PLLC
1202 Medical Ctr Dr, 
Wilmington, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kevin Cannon is a Hospital Medicine provider in Wilmington, North Carolina. Dr. Cannon is highly rated in 1 condition, according to our data. His top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Liver Failure, Endoscopy, and Gastrostomy. Dr. Cannon is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hospital Medicine
Licenses
Hospitalist in NC
Hospital Affiliations
Novant Health New Hanover Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

WILMINGTON HEALTH PLLC
1202 Medical Ctr Dr, Wilmington, NC 28401

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
A Phase 1/2, Randomized, Observer-Blind, Dose-Finding, Controlled, Parallel-Group, Two-Stage Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Adults Aged 18 to 64 Years
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological, Other
Study Drug: SARS-CoV-2 rS/Matrix-M1 Adjuvant
Study Phase: Phase 3
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
View 5 Less Clinical Trials

1 Total Publications

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Journal: The New England journal of medicine
Published: March 23, 2022
Similar Doctors
Expertise in
1
conditions
Dr. Lucas H. Faulkenberry
Hospital Medicine
Expertise in
1
conditions
Dr. Lucas H. Faulkenberry
Hospital Medicine

Novant Health Medical Group Coastal Region LLC

2131 S 17th St, 
Wilmington, NC 
 (0.5 miles away)
910-662-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lucas Faulkenberry is a Hospital Medicine provider in Wilmington, North Carolina. Dr. Faulkenberry is highly rated in 1 condition, according to our data. His top areas of expertise are Liver Failure, Heart Failure with Preserved Ejection Fraction (HFpEF), Endoscopy, and Gastrostomy. Dr. Faulkenberry is currently accepting new patients.

Expertise in
61
conditions
Dr. Jason K. Boyd
Hematology Oncology | Hospital Medicine | Hematology
Expertise in
61
conditions
Dr. Jason K. Boyd
Hematology Oncology | Hospital Medicine | Hematology

Southeastern Medical Oncology Center

211 Beaman St, 
Clinton, NC 
 (59.6 miles away)
910-592-5727
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Boyd is a Hematologist Oncology specialist and a Hospital Medicine provider in Clinton, North Carolina. Dr. Boyd is highly rated in 61 conditions, according to our data. His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Boyd is currently accepting new patients.

Expertise in
2
conditions
Dr. Neha N. Doctor
Hospital Medicine
Expertise in
2
conditions
Dr. Neha N. Doctor
Hospital Medicine

Vidant Medical Group LLC

401 N Main St, 
Kenansville, NC 
 (52.7 miles away)
910-296-0941
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neha Doctor is a Hospital Medicine provider in Kenansville, North Carolina. Dr. Doctor is highly rated in 2 conditions, according to our data. Her top areas of expertise are Heart Failure with Preserved Ejection Fraction (HFpEF), Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrial Tachycardia, Pacemaker Implantation, and Endoscopy. Dr. Doctor is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cannon's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile